Literature DB >> 30935797

Anticancer platinum(II) complexes bearing N-heterocycle rings.

Giorgio Facchetti1, Isabella Rimoldi2.   

Abstract

Starting from the pioneering discovery of picoplatin and phenanthriplatin, many efforts were realized by different research groups in the synthesis of different platinum(II) complexes, bearing a N-heterocycle moiety active as anticancer agents in different types of solid tumors. This review deals in particular with both the bifunctional and monofunctional platinum drugs, not only in dichloride platinum(II) complexes, but also in recent advances in modern platinum structures, i.e. cationic ones. Both the in vitro and in vivo studies of these anticancer agents are taken into account, with a special consideration for aggressive and orphan in treatment tumors.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bifunctional complex; Cancer therapy; Monofunctional complex; Platinum(II) complex; Tumor cell lines

Year:  2019        PMID: 30935797     DOI: 10.1016/j.bmcl.2019.03.045

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  9 in total

1.  Monofunctional platinum(II) compounds and nucleolar stress: is phenanthriplatin unique?

Authors:  Christine E McDevitt; Matthew V Yglesias; Austin M Mroz; Emily C Sutton; Min Chieh Yang; Christopher H Hendon; Victoria J DeRose
Journal:  J Biol Inorg Chem       Date:  2019-09-07       Impact factor: 3.358

2.  The monofunctional platinum(II) compounds, phenanthriplatin and pyriplatin, modulate apoptosis signaling pathways in HEI-OC1 auditory hybridoma cells.

Authors:  Jerry D Monroe; Alexandra M Johnston; Michael E Smith
Journal:  Neurotoxicology       Date:  2020-05-13       Impact factor: 4.294

3.  Biological Properties of New Chiral 2-Methyl-5,6,7,8-tetrahydroquinolin-8-amine-based Compounds.

Authors:  Giorgio Facchetti; Michael S Christodoulou; Lina Barragán Mendoza; Federico Cusinato; Lisa Dalla Via; Isabella Rimoldi
Journal:  Molecules       Date:  2020-11-27       Impact factor: 4.411

4.  New Benzimidazole-, 1,2,4-Triazole-, and 1,3,5-Triazine-Based Derivatives as Potential EGFRWT and EGFRT790M Inhibitors: Microwave-Assisted Synthesis, Anticancer Evaluation, and Molecular Docking Study.

Authors:  Heba E Hashem; Abd El-Galil E Amr; Eman S Nossier; Manal M Anwar; Eman M Azmy
Journal:  ACS Omega       Date:  2022-02-18

5.  Synthesis, biological evaluation, and in silico studies of novel chalcone- and pyrazoline-based 1,3,5-triazines as potential anticancer agents.

Authors:  Leydi M Moreno; Jairo Quiroga; Rodrigo Abonia; Antonino Lauria; Annamaria Martorana; Henry Insuasty; Braulio Insuasty
Journal:  RSC Adv       Date:  2020-09-15       Impact factor: 4.036

6.  New Bis-Cyclometalated Iridium(III) Complexes with β-Substituted Porphyrin-Arylbipyridine as the Ancillary Ligand: Electrochemical and Photophysical Insights.

Authors:  Nuno M M Moura; Vanda Vaz Serra; Alexandre Bastos; Juliana C Biazotto; Kelly A D F Castro; Maria Amparo F Faustino; Carlos Lodeiro; Roberto S da Silva; Maria da Graça P M S Neves
Journal:  Int J Mol Sci       Date:  2022-07-09       Impact factor: 6.208

Review 7.  Development of Photoremovable Linkers as a Novel Strategy to Improve the Pharmacokinetics of Drug Conjugates and Their Potential Application in Antibody-Drug Conjugates for Cancer Therapy.

Authors:  Audrey Nathania Johan; Yi Li
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-25

8.  p-Cymene Complexes of Ruthenium(II) as Antitumor Agents.

Authors:  María Angeles Pujante-Galián; Sergio A Pérez; Mercedes G Montalbán; Guzmán Carissimi; Marta G Fuster; Gloria Víllora; Gabriel García
Journal:  Molecules       Date:  2020-10-31       Impact factor: 4.411

9.  In Vitro Activity of Monofunctional Pt-II Complex Based on 8-Aminoquinoline against Human Glioblastoma.

Authors:  Valentina Coccè; Isabella Rimoldi; Giorgio Facchetti; Emilio Ciusani; Giulio Alessandri; Lucia Signorini; Francesca Sisto; Aldo Giannì; Francesca Paino; Augusto Pessina
Journal:  Pharmaceutics       Date:  2021-12-07       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.